Objectives: TREAT is a computerized decision support system for antibiotic treatment. In a randomized controlled trial it improved significantly the percentage of appropriate empirical antibiotic treatment and shortened hospital stay, while the usage of broad-spectrum antibiotics was reduced. The trial was not powered to show significance for the difference in 1 month mortality rate. In the present analysis we looked at 6 month survival in one of the hospitals (Beilinson Hospital) that participated in the trial. Results: At Beilinson Hospital 1683 patients were included in the study, 860 in the intervention arm and 823 in the control arm. In the ITTanalysis 180 day survival in control patients was 71% versus 74% in the intervention patients (P ¼0.2). In the PP analysis the survival percentages were 71% and 77%, respectively (P ¼ 0.04). In patients with bacterial infections, in the ITTanalysis 180 day survival in the control group was 68% versus 71% in the intervention patients (P ¼0.1). In the PP analysis the survival percentages were 68% versus 74% (P¼ 0.04).
Introduction
TREAT is a decision support system for antibiotic treatment of inpatients with moderate to severe bacterial infections. It uses causal probabilistic networks populated with local data and patients' clinical data 1 to predict the probability of a bacterial infection, site of infection and pathogens 2 and their susceptibility to antibiotics. It then applies a cost -benefit model to rank antibiotic treatments according to their net benefit (taking into account the cost of future resistance) and offer advice. 3 TREAT was tested in a cluster-randomized clinical trial: 15 wards in three hospitals were randomized and 2326 patients participated in the study. 4 The percentage of appropriate empirical antibiotic treatment was 64% in the control wards versus 73% in the intervention ward in the intention-to-treat (ITT) analysis and 64% versus 85% in the per protocol (PP) analysis (both comparisons were statistically significant). Hospital stay was shorter in the intervention wards and the usage of broad-spectrum antibiotics was reduced in these departments. 4 Thirty day mortality was reduced from 14.3% to 12.9%. In the 1683 patients recruited in Israel, the reduction in 30 day mortality was 2.5 percentage points (15.6% versus 13.1%). The study was not powered to show statistical significance for the reduction in 30 day mortality rates.
Since strong evidence shows that severe infections have longterm consequences and that appropriate empirical antibiotic treatment might mitigate these, 5 we decided to look at the 6 month survival of patients who were randomized to control and intervention in the TREAT trial in Israel.
Methods
The methods of the TREAT trial are detailed in a previous publication. 4 In short, 15 medical wards in three hospitals (one each in Germany, Italy and Israel) were randomized to intervention (the TREAT system was installed and physicians were encouraged to use it) and control (local guidelines were implemented). Included were patients prescribed an antibiotic drug for therapy of an infection, septic patients and patients from whom blood cultures were drawn. Patients with suspected tuberculosis or suspected infections related to travel, transplant patients and patients with AIDS were excluded. For the present analysis we looked at the 180 day survival rates in Israeli patients who were included in the trial. Date of death is imported to the hospital records from the Ministry of Internal Affairs Population Registry. We plotted the Kaplan-Meier survival function. Survival was compared using the Wilcoxon test, which places more weight on the early periods of time. We performed an ITTanalysis (all patients who were hospitalized in the participating wards and fitted the inclusion criteria) and a PP analysis (all patients in the control wards and patients for whom the physicians applied one of the top three TREAT recommendations in the intervention wards). We looked separately at patients with a clinically or microbiologically documented bacterial infection. The definitions of microbiologically documented bacterial infections are given in the original report. 4 To define clinically documented bacterial infections, CDC definitions 6 were translated into computerized rules and run through the database.
The Research Ethics Committee at Rabin Medical Center approved the analysis.
Results
In Israel 1683 patients were included in the study, 860 in the intervention arm and 823 in the control arm. Comparisons between the two groups are presented in Table 1 . There were no significant differences between the intervention and control arms or between the ITT and PP populations of the intervention arm. Two-hundred-andthirty-seven patients (29%) included in the control group died during 180 days of follow-up, versus 229 (27%) in the intervention group. In the PP analysis the number of deaths was 237 (29%) in the control group versus 81 out of 344 (24%) in the intervention group.
In the ITT analysis 180 day survival in control patients was 71% versus 74% in the intervention patients (P ¼ 0.2, Figure 1a) . In the PP analysis the survival percentages were 71% and 77%, respectively (P ¼ 0.04, Figure 1b) .
We repeated the analysis in patients with documented bacterial infections (675 patients in the ITT intervention group, 280 in the PP intervention group and 657 in the control group). In the ITTanalysis the 180 day survival in the control group was 68% versus 71% in the intervention patients (P ¼ 0.1, Figure 2a) . In the PP analysis the survival percentage was 68% versus 74% (P ¼ 0.04, Figure 2b ).
Discussion
In the present analysis we were able to show that the improvement in empirical antibiotic treatment achieved by TREAT translates into Long-term survival in TREAT RCT an increase in 180 day survival rates. In patients with bacterial infection, mortality rates were decreased by 3% (a relative decrease of 9%) in the ITT analysis and by 6% (a relative decrease of 19%) in patients treated according to the TREATadvice. The ITTanalysis did not reach conventional statistical significance, although the absolute survival in the intervention group was better (Figures 1a and  2a) . The ITTanalysis included .20% of patients without a bacterial infection, in whom the gain in survival was expected to be minimal. The similarity in the survival curves of the ITT and PP groups supports a real effect on survival.
In the TREAT trial the physicians were encouraged to employ the TREAT system, but we emphasized that the final decision was in the hands of the physician. The present results should encourage a more proactive policy of convincing physicians to adopt the system's advice.
There are several limitations to the present analysis. Six month survival was not among the pre-planned outcomes of the original trial. In the present analysis we show results for only one of the participant hospitals. As for every 'treated PP' analysis, we cannot be sure whether patients with better prognosis were not selected to be treated according to the TREAT advice in the intervention group. This is probably not a major limitation, since the patients included in the PP analysis were quite similar to the patients of the control group (Table 1) .
The main difficulty of interpreting cluster randomized trials [the differences measured might be between clusters (wards) and not due to the intervention] probably does not exist in the present analysis. The patients were well balanced between the intervention and control arms. In an observational study conducted immediately before the trial all outcomes were identical in the control and intervention wards. 4 In conclusion, the present data support an effect of the TREAT decision support system on 6 month survival, mainly because of its benefit in patients with documented bacterial infections, as expected. The reduction in use of broad-spectrum antibiotics and hospital stay, together with the improved 6 month survival, renders the TREAT system a valuable tool in our armamentarium against bacterial infection and resistance to antibiotic drugs. Leibovici et al.
